Cardiovascular diseases are the leading cause of death worldwide, with 17.9 million deaths annually, a number expected to reach 22 million by 2030, according to the WHO. In Catalonia, one in four people will die from coronary disease, affecting around 250,000 individuals.
Bellvitge Hospital and IDIBELL have joined the European GRACE project (bridGing gaps in cardiac health management), an initiative funded by the Innovative Health Initiative (IHI) and supported by 25 international partners. The project aims to revolutionize cardiovascular disease management through artificial intelligence, telemedicine, and digital solutions.
oordinated by the University Campus Bio-Medico of Rome and Medtronic Ibérica, GRACE has a budget of €19.16 million and runs for 54 months. It includes six clinical pilots in Europe to validate AI-based solutions for heart failure, atrial fibrillation, and aortic stenosis. Bellvitge Hospital, through its Multidisciplinary Community Heart Failure Care Unit (UMICO), will participate in the HF-CardioGuard pilot, a clinical trial testing AI and telemedicine tools to optimize patient management. Conducted in Bellvitge, Viladecans, and three hospitals in Rome, the trial will assess a real-time telemonitoring platform capable of generating personalized alerts to improve care. These innovations aim to reduce unnecessary hospitalizations, improve patient quality of life, and enhance heart failure management. IDIBELL will contribute to data analysis and clinical impact evaluation.
GRACE seeks to develop scalable, interoperable technologies for early disease detection, improved care coordination, personalized treatments, and better patient adherence, ensuring their efficient integration into European healthcare systems.
Article written by IMMédico Team
17/03/2025
Source:
IMMédico